342578-12-5 Usage
Description
(1r,4r)-4-(1,1-dimethylethylsulfonamido)cyclohexanecarboxylic acid, also known as trans-4-(1,1-dimethylethylsulfonamido)cyclohexanecarboxylic acid, is an organic compound that serves as an intermediate in the synthesis of pharmaceuticals. It is characterized by its unique stereochemistry and functional groups, which contribute to its potential applications in medicinal chemistry.
Used in Pharmaceutical Industry:
(1r,4r)-4-(1,1-dimethylethylsulfonamido)cyclohexanecarboxylic acid is used as an intermediate in the synthesis of Velneprit (V115000) for the development of pharmaceuticals. Velneprit is an optimized synthetic neuropeptide Y (NPY) Y5 receptor antagonist, which is utilized in the oral treatment of obesity. Its role in the synthesis process is crucial for the production of this therapeutic agent, targeting the NPY Y5 receptor to help manage weight and improve metabolic health in patients.
Check Digit Verification of cas no
The CAS Registry Mumber 342578-12-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,2,5,7 and 8 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 342578-12:
(8*3)+(7*4)+(6*2)+(5*5)+(4*7)+(3*8)+(2*1)+(1*2)=145
145 % 10 = 5
So 342578-12-5 is a valid CAS Registry Number.
342578-12-5Relevant articles and documents
Development of an optimized synthetic and purification process of S-2367 (Velneperit), a novel neuropeptide y (NPY) Y5 receptor antagonist
Oda, Shinichi,Manaka, Kumiko,Kakiya, Kiyoshi,Hozumi, Yasuyuki,Fukui, Yuki,Omura, Sohei,Kurashita, Makoto,Nishiwaki, Masanori,Takeuchi, Yoshiyuki,Kitamura, Hideyuki
, p. 531 - 536 (2015/04/27)
We developed a simple synthetic route to S-2367 (Velneperit) (1) using trans-1-ethoxycarbonyl-4-aminocyclohexane hydrochloride salt (12) as a starting material. The key step was Na2WO4/H2O2 oxidation, and we found that it was accelerated in weakly basic conditions. The finding was useful to control one of the critical impurities: 14 in 10. The new process was more efficient than the early process from the viewpoint of the number of reactions, yield, throughput, and EHS (environment, health, and safety) but a quality deviation occurred in the pilot manufacturing: 10 content in 1 was over the upper limit. The cause was presumed to be hydrolysis of 1 during the recrystallization step. After finding it, we developed two reliable purification processes. The first was slurry washing including clever polymorphic control using only acetone and water. The second was salt formation of 10 and rational building of the recrystallization procedure based on solubility to improve removal rate.
